Cullinan Oncology Q3 EPS $(0.91) Beats $(0.92) Estimate; Cash And Investment Position Of $482M Expected To Provide Runway Into 2H Of 2026, Vs Into 2026 Previously
Portfolio Pulse from Benzinga Newsdesk
Cullinan Oncology (NASDAQ:CGEM) reported Q3 losses of $(0.91) per share, beating the analyst consensus estimate of $(0.92) by 1.09 percent. This is a 10.98 percent decrease over losses of $(0.82) per share from the same period last year. The company's cash and investment position of $482M is expected to provide a runway into the second half of 2026.
November 08, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cullinan Oncology reported better than expected Q3 losses and has a strong cash position, which could positively impact its stock in the short term.
Cullinan Oncology's better than expected Q3 results and strong cash position could make the stock more attractive to investors, potentially leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100